

- **TITANBRIDGE® (medical device): Otorhinolaryngology**
 - Unique technology of curative treatment for adductor spasmodic dysphonia developed in Japan ahead of the world by Dr. Nobuhiko Isshiki, Professor Emeritus, Kyoto Univ.
 - Indication: Improvement in symptoms of adductor spasmodic dysphonia
 - Intractable disease with unknown cause
 - Dysphonia due to involuntary intermittent tremor of intralaryngea muscle during phonation
 - No lesion nor paralysis in vocal cord
 - Phoniatics and psychotherapy ineffective
 - No curative treatment available globally to date
 - Jul 2015: Investigator initiated trial (Kumamoto Univ., etc.)
 - Feb 2016: 1st SAKIGAKE* designation for medical device
 - Sep 2016: Orphan designation
 - Jun 2017: Japanese NDA filed
 - Dec 2017: Approved in Japan (First among SAKIGAKE designated products)
 - Jun 2018: National Health Insurance listed
 - Jul 2018: Launch in Japan

*SAKIGAKE: Fast-track review system to promote R&D in Japan aiming at early practical application for innovative pharmaceutical products/medical devices/regenerative medicines